Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure

American Journal of Transplantation

Volumn 5, Issue 8, 2005, Pages 2005-2010

  Filler, Guido ^a   Womiloju, Taiwo ^a   Feber, Janusz ^a   Lepage, Nathalie ^a   Christians, Uwe ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Children; Drug clearance; Drug interaction; Sirolimus; Tacrolimus

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; CHILD; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 22844442933     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00963.x     Document Type: Article

References (16)

1. Hodges CB, Maxwell H, Beattie TJ, Murphy AV, Jindal RM. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity. Pediatr Nephrol 2001; 16: 777-778.
2. Schachter AD, Meyers KE, Spaneas LD et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004; 8: 171-177.
3. Bai S, Stepkowski SM, Kahan BD et al. Metabolic interaction between cyclosporine and sirolimus. Transplantation 2004; 77: 1507-1512.
4. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244-251.
5. Sindhi R, Webber S, Venkataramanan R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001; 72: 851-855.
6. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies [Review]. Nephrol Dial Transplant 2003; 18: 2-5.
7. Schubert M, Venkataramanan R, Holt DW et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004; 4: 767-773.
8. Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003; 18: 981-985.
9. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
10. CDER (1999) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologies Evaluation and Research (CBER). Guidance for the Industry. In: Vivo drug metabolism/drug interaction studies- study design, data analysis, and recommendations for dosing and labeling. November 1999 (Available at www.fda.gov/cder/guidance).
11. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562-1566.
12. Garbe E, Röhmel J, Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 1993; 45: 1-7.
13. Lampen A, Zhang Y, Hackbarth I et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998; 285: 1104-1112.
14. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus [Review], Clin Pharmacokinet 2002; 41: 813-851.
15. Christians U. Transport proteins and intestinal metabolism. P-glycoprotein and cytochrome P4503A. Ther Drug Monit 2004; 26: 104-106.
16. Deters M, Klabunde T, Kirchner G, Resch K, Kaever V. Sirolimus/ cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. Br J Pharmacol 2002; 136: 604-612.